Cargando…

Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression

Major depressive disorder (MDD) is a highly prevalent and devastating psychiatric illness with strong individual and societal burdens. However, biomarkers to improve the limited preventive and therapeutic approaches are scarce. Multilevel evidence suggests that the pathophysiological involvement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mühle, Christiane, Wagner, Claudia Johanna, Färber, Katharina, Richter-Schmidinger, Tanja, Gulbins, Erich, Lenz, Bernd, Kornhuber, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617165/
https://www.ncbi.nlm.nih.gov/pubmed/31200571
http://dx.doi.org/10.3390/jcm8060846
_version_ 1783433628811788288
author Mühle, Christiane
Wagner, Claudia Johanna
Färber, Katharina
Richter-Schmidinger, Tanja
Gulbins, Erich
Lenz, Bernd
Kornhuber, Johannes
author_facet Mühle, Christiane
Wagner, Claudia Johanna
Färber, Katharina
Richter-Schmidinger, Tanja
Gulbins, Erich
Lenz, Bernd
Kornhuber, Johannes
author_sort Mühle, Christiane
collection PubMed
description Major depressive disorder (MDD) is a highly prevalent and devastating psychiatric illness with strong individual and societal burdens. However, biomarkers to improve the limited preventive and therapeutic approaches are scarce. Multilevel evidence suggests that the pathophysiological involvement of sphingolipids particularly increases the levels of ceramides and the ceramide hydrolyzing enzyme, acid sphingomyelinase. The activity of secretory acid sphingomyelinase (S-ASM) and routine blood parameters were determined in the serum of patients with current (unmedicated n = 63, medicated n = 66) and remitted (n = 39) MDD and healthy subjects (n = 61). Depression severity and anxiety and their 3-weeks prospective course of treatment were assessed by psychometric inventories. S-ASM activity was not different between the four groups, did not decrease during treatment, and was not lower in individuals taking medication that functionally inhibited ASM. However, S-ASM correlated positively with depression severity only in remitted patients. High enzyme activity at inclusion predicted milder clinician-evaluated and self-rated depression severity (HAM-D, MADRS, BDI-II) and state anxiety at follow-up, and was related to stronger improvement in these scores in medicated patients. S-ASM was strongly and contrariwise associated with serum lipids in unmedicated and medicated females. These findings contribute to a better understanding of the pathomechanisms underlying depression and the development of clinical strategies and biomarkers.
format Online
Article
Text
id pubmed-6617165
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66171652019-07-18 Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression Mühle, Christiane Wagner, Claudia Johanna Färber, Katharina Richter-Schmidinger, Tanja Gulbins, Erich Lenz, Bernd Kornhuber, Johannes J Clin Med Article Major depressive disorder (MDD) is a highly prevalent and devastating psychiatric illness with strong individual and societal burdens. However, biomarkers to improve the limited preventive and therapeutic approaches are scarce. Multilevel evidence suggests that the pathophysiological involvement of sphingolipids particularly increases the levels of ceramides and the ceramide hydrolyzing enzyme, acid sphingomyelinase. The activity of secretory acid sphingomyelinase (S-ASM) and routine blood parameters were determined in the serum of patients with current (unmedicated n = 63, medicated n = 66) and remitted (n = 39) MDD and healthy subjects (n = 61). Depression severity and anxiety and their 3-weeks prospective course of treatment were assessed by psychometric inventories. S-ASM activity was not different between the four groups, did not decrease during treatment, and was not lower in individuals taking medication that functionally inhibited ASM. However, S-ASM correlated positively with depression severity only in remitted patients. High enzyme activity at inclusion predicted milder clinician-evaluated and self-rated depression severity (HAM-D, MADRS, BDI-II) and state anxiety at follow-up, and was related to stronger improvement in these scores in medicated patients. S-ASM was strongly and contrariwise associated with serum lipids in unmedicated and medicated females. These findings contribute to a better understanding of the pathomechanisms underlying depression and the development of clinical strategies and biomarkers. MDPI 2019-06-13 /pmc/articles/PMC6617165/ /pubmed/31200571 http://dx.doi.org/10.3390/jcm8060846 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mühle, Christiane
Wagner, Claudia Johanna
Färber, Katharina
Richter-Schmidinger, Tanja
Gulbins, Erich
Lenz, Bernd
Kornhuber, Johannes
Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression
title Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression
title_full Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression
title_fullStr Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression
title_full_unstemmed Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression
title_short Secretory Acid Sphingomyelinase in the Serum of Medicated Patients Predicts the Prospective Course of Depression
title_sort secretory acid sphingomyelinase in the serum of medicated patients predicts the prospective course of depression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617165/
https://www.ncbi.nlm.nih.gov/pubmed/31200571
http://dx.doi.org/10.3390/jcm8060846
work_keys_str_mv AT muhlechristiane secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression
AT wagnerclaudiajohanna secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression
AT farberkatharina secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression
AT richterschmidingertanja secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression
AT gulbinserich secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression
AT lenzbernd secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression
AT kornhuberjohannes secretoryacidsphingomyelinaseintheserumofmedicatedpatientspredictstheprospectivecourseofdepression